PMID- 30543763
OWN - NLM
STAT- MEDLINE
DCOM- 20200323
LR  - 20200323
IS  - 1935-469X (Electronic)
IS  - 1554-7477 (Linking)
VI  - 15
IP  - 1
DP  - 2019 Jan
TI  - Role of Adverse Events in Unscheduled Hospitalizations Among Patients With Solid 
      Tumors Who Receive Medical Oncology Treatment.
PG  - e39-e45
LID - 10.1200/JOP.18.00319 [doi]
AB  - PURPOSE: The development of strategies to prevent or mitigate cancer 
      treatment-related adverse events (AEs) is necessary to improve patient 
      experience, safety, and cost containment. To develop a strategy to easily 
      identify and mitigate AEs, we sought to understand the frequency and severity of 
      those that resulted in hospitalizations. METHODS: We retrospectively 
      characterized hospitalizations of ambulatory adult patients with solid tumor 
      cancers within 30 days of chemotherapy administration using medical record data 
      abstraction. Hospitalizations were categorized as caused by cancer symptoms, a 
      noncancer medical condition, or a medical oncology treatment-related AE. Severity 
      of the treatment-related AE hospitalization was rated using the National Patient 
      Safety Agency risk assessment matrix scale. RESULTS: Between May and October 
      2016, 116 patients experienced 197 hospitalizations (per-patient mean, 1.7 AEs; 
      range, 1 to 7 AEs). Sixty-six percent (n = 130) of hospitalizations were related 
      to cancer symptoms, whereas 19.3% (n = 38) were treatment-related AE 
      hospitalizations. The median length of stay of hospitalizations that resulted 
      from an AE was 6 days (interquartile range, 3 to 9 days), and 36.8% had more than 
      1 AE. GI symptoms accounted for 48.1% of AEs, and neutropenic fever accounted for 
      11.1%. Sixty-one percent of treatment-related AE hospitalizations were 
      characterized as moderate severity. CONCLUSION: Hospitalizations in patients with 
      solid tumors as a direct result of their medical oncology care treatment are not 
      uncommon. These findings argue for novel approaches, such as automated trigger 
      tools, to identify and manage complications of medical oncology treatment before 
      hospitalization is needed. Improved outpatient management of cancer symptoms may 
      have a dramatic impact on hospitalizations for patients with cancer.
FAU - Wong, Chris I
AU  - Wong CI
AD  - 1 Dana-Farber Cancer Institute, Boston, MA.
AD  - 2 Boston Children's Hospital, Boston, MA.
FAU - Zerillo, Jessica A
AU  - Zerillo JA
AD  - 3 Beth Israel Deaconess Medical Center, Boston, MA.
FAU - Stuver, Sherri O
AU  - Stuver SO
AD  - 1 Dana-Farber Cancer Institute, Boston, MA.
AD  - 4 Boston University School of Public Health, Boston, MA.
FAU - Siegel, Jocelyn H
AU  - Siegel JH
AD  - 1 Dana-Farber Cancer Institute, Boston, MA.
FAU - Jacobson, Joseph O
AU  - Jacobson JO
AD  - 1 Dana-Farber Cancer Institute, Boston, MA.
FAU - McNiff, Kristen K
AU  - McNiff KK
AD  - 1 Dana-Farber Cancer Institute, Boston, MA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20181213
PL  - United States
TA  - J Oncol Pract
JT  - Journal of oncology practice
JID - 101261852
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents/*adverse effects
MH  - Female
MH  - Hospitalization/*statistics & numerical data
MH  - Humans
MH  - Male
MH  - Medical Oncology
MH  - Middle Aged
MH  - Neoplasms/*drug therapy
MH  - Retrospective Studies
EDAT- 2018/12/14 06:00
MHDA- 2020/03/24 06:00
CRDT- 2018/12/14 06:00
PHST- 2018/12/14 06:00 [pubmed]
PHST- 2020/03/24 06:00 [medline]
PHST- 2018/12/14 06:00 [entrez]
AID - 10.1200/JOP.18.00319 [doi]
PST - ppublish
SO  - J Oncol Pract. 2019 Jan;15(1):e39-e45. doi: 10.1200/JOP.18.00319. Epub 2018 Dec 
      13.